Estrella Immunopharma (ESLAW) Competitors $0.04 -0.01 (-19.60%) As of 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ESLAW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. Estrella Immunopharma vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene Estrella Immunopharma (NASDAQ:ESLAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Is ESLAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A N/A N/A 180 Life Sciences N/A N/A N/A Which has better valuation & earnings, ESLAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the media refer more to ESLAW or ATNFW? In the previous week, Estrella Immunopharma had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for 180 Life Sciences. Estrella Immunopharma's average media sentiment score of 1.91 beat 180 Life Sciences' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Very Positive 180 Life Sciences Neutral SummaryEstrella Immunopharma beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLAW vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$235.66M$5.73B$10.28BDividend YieldN/A3.78%5.88%4.63%P/E RatioN/A41.1976.6726.53Price / SalesN/A4,772.57525.87121.13Price / CashN/A13.1937.2060.52Price / BookN/A141.9713.946.31Net IncomeN/A-$90.99M$3.29B$271.37M7 Day PerformanceN/A1.01%0.64%2.11%1 Month PerformanceN/A20.29%4.32%6.67%1 Year PerformanceN/A836.17%84.14%27.85% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAWEstrella ImmunopharmaN/A$0.04-19.6%N/AN/A$0.00N/A0.00N/APositive NewsHigh Trading VolumeATNFW180 Life SciencesN/A$0.10-43.6%N/A+1,069.2%$0.00N/A0.007Gap UpHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.05-5.7%N/A+19.0%$0.00$641.41K0.002Gap DownDRTSWAlpha Tau MedicalN/A$0.30+0.7%N/A+50.9%$0.00N/A0.0080APLMWApollomicsN/A$0.02-3.2%N/A+108.8%$0.00N/A0.0059Positive NewsShort Interest ↓Gap DownTrading HaltedBCTXWBriaCell TherapeuticsN/A$0.03+4.6%N/A-79.2%$0.00N/A0.008CDIOWCardio DiagnosticsN/A$0.02-4.0%N/AN/A$0.00$19.51K0.007Positive NewsShort Interest ↓Gap UpCELUWCelularityN/A$0.05+10.9%N/A+224.0%$0.00$44.59M0.00220Positive NewsGap UpCEROWCERo TherapeuticsN/A$0.01+1.4%N/A+138.3%$0.00N/A0.008Positive NewsCINGWCingulateN/A$0.05-4.0%N/A-29.9%$0.00N/A0.0020Positive NewsGap UpCLNNWCleneN/A$0.03-4.4%N/A-35.2%$0.00$286K0.00100Positive NewsGap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Celularity Competitors CERo Therapeutics Competitors Cingulate Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLAW) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
